Tyrosine Kinase Inhibitors' Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in...

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are crucial in cancer therapy, particularly pazopanib for metastatic renal cell carcinoma.
• TKIs are associated with various endocrine adverse effects, including hypothyroidism and hypogonadism.
• Adrenal insufficiency is a rarely reported TKI-associated endocrine dysfunction.

Observation:

• This article details the first reported case of pazopanib-induced primary adrenal insufficiency.
• The patient had metastatic renal cell carcinoma and presented with symptoms after pazopanib treatment.
• Other causes of primary adrenal insufficiency were systematically excluded.

Findings:

• Pazopanib was identified as the causative agent for primary adrenal insufficiency.
• The mechanism may involve adrenal toxicity, potentially leading to hemorrhage or necrosis.
• This case highlights a significant, albeit rare, endocrine complication of pazopanib therapy.

Implications:

• Clinicians should consider primary adrenal insufficiency in patients on pazopanib presenting with relevant symptoms.
• Early diagnosis and management of pazopanib-induced adrenal insufficiency are crucial.
• Further research is needed to understand the prevalence and precise mechanisms of TKI-induced adrenal toxicity.